Shenogen’s Icaritin: A New First-Line Therapy For HCC?
This article was originally published in PharmAsia News
Executive Summary
Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.
You may also be interested in...
China Investment Roundup: Spotlight On Oncology
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.